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Mesenchymal stem cells (MSCs) have the capabilities
for self-renewal and differentiation into cells with the
phenotypes of bone, cartilage, neurons and fat cells. These
features of MSCs have attracted the attention of
investigators for using MSCs for cell-based therapies to
treat several human diseases. Because bone marrow-
derived cells, which are a main source of MSCs, are not
always acceptable due to a significant drop in their cell
number and proliferative/differentiation capacity with
age, human umbilical cord blood (UCB) cells are good
substitutes for BMCs due to the immaturity of newborn
cells. Although the isolation of hematopoietic stem cells
from UCB has been well established, the isolation and
characterization of MSCs from UCB still need to be
established and evaluated. In this study, we isolated and
characterized MSCs. UCB-derived mononuclear cells, which
gave rise to adherent cells, exhibited either an osteoclast
or a mesenchymal-like phenotype. The attached cells
with mesenchymal phenotypes displayed fibroblast-like
morphologies, and they expressed mesenchym-related
antigens (SH2 and vimentin) and periodic acid Schiff
activity. Also, UCB-derived MSCs were able to trans-
differentiate into bone and 2 types of neuronal cells, in
vitro. Therefore, it is suggested that the MSCs from UCB
might be a good alternative to bone marrow cells for
transplantation or cell therapy. 
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Introduction
The blood remaining in the umbilical cord following birth
contains hematopoietic precursors and this has become an
important alternative source for transplantation of hematopoietic
stem cells [2,7,8,11,14]. However, there is controversy as to
whether umbilical cord blood (UCB) contains mesenchymal
stem cells (MSCs) that are capable of differentiating into
cells of different connective tissue lineages such as bone,
cartilage and adipose tissues, and these cells are the best
candidates for tissue engineering of musculoskeletal tissues
[17,20,26]. To date, the most common source of MSCs has
been bone marrow, but aspirating bone marrow from the
patient is an invasive, painful procedure. In addition, it has
been demonstrated that the number of bone marrow MSCs
and their ability to differentiate decreases with age [4,15].
Therefore, researchers are looking for alternative sources of
MSCs. So far, little success has been reported about the
isolation, characterization and differentiation of MSCs from
UCB. Erices et al. [5] have reported that UCB-derived
mononuclear cells gave rise to 2 adherent cell types, and one
of them expressed MSC-related surface antigens. Mareschi
et al. [16] reported that under given conditions, it was
possible to isolate MSCs from bone marrow, but not from
UCB. However, Goodwin et al. [9] have recently reported
the multi-lineage differentiation ability of UCB-isolated
cells; these cells express bone, fat and neural markers.
Kakinuma et al. [13] reported that they could differentiate
UCB cells into hepatic progenitor cells. Neither of these
reports provided sufficient evidence to fulfill the criteria for
qualifying MSCs because both research groups found
relatively heterogeneous cells. Wexler et al. [26] have
recently reported that UCB is not a rich source of human
MSCs, while Romanov et al. [20] also suggested using
umbilical cord endothelial cells as an alternative MSC
source. Nevertheless, UCB cells have many advantages
because of the immaturity of newborn cells compared with
adult cells. Furthermore, UCB provides no ethical problems
for basic studies and clinical applications. Further, UCB
cells can be collected without any harm to the newborn
infant. In this study, we examined whether MSCs from UCB
could expand their population and if they have the ability to
differentiation to bone and neuronal cell types. We also
investigated how to purify MSCs from the heterogeneous
cell types.
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Materials and Methods
Cell collection
UCB cells were obtained from normal full-term and pre-
term deliveries at Seoul National University Borame Hospital
(Seoul, Korea) according to the institutional guidelines. The
blood was collected into 250 ml standard blood collection
bags (Green Cross, Korea) that contained citrate-phosphate-
dextrose anticoagulant.
Cell processing
The buffy coat cells were obtained by centrifugation (400
g for 20 min), and the low-density mononuclear cells
(MNC, <1.077 g/ml) were isolated using Ficoll-Paque Plus
(Amersham Biosciences, Sweden). The cells were then
resuspended in Dulbeco’s Modified Eagle low glucose
medium (Gibco-BRL, USA) that was supplemented with
10% fetal bovine serum (FBS; Gibco-BRL, USA). The total
numbers of nucleated and viable cells were determined with
a hemocytometer and by using trypan blue stain [10].
Isolation and culture of MSCs
The cells were cultured in growth medium [Dulbeco’s
Modified Eagle Media-low glucose with the addition of
10% FBS with 2 mmol/l L-glutamine (Gibco-BRL, USA)]
and 0.3% penicillin-streptomycin (Gibco-BRL, USA) at
37
oC and a 5% CO2 concentration. The cells were initially
plated into a 10 to 175 cm
2 tissue culture flask (Nunc, USA)
at a density of 1.5 × 10
6 mononuclear cells/cm
2. The cells
were transferred to new flask to remove the platelets after
1 day of culture. Half the medium was changed weekly
thereafter. The cells were passaged by trypsinization (0.05%
trypsin/EDTA solution; Gibco BRL, USA) upon reaching
50% to 60% confluence (5,000-6,000 cells/cm
2), and they
were replated at a density of 1,000 to 2,000 cells/cm
2 [9].
Cytochemical and immunophenotyping of MSCs and
characterization of MSCs
Cells in situ were analyzed for the following cytochemical
markers: acid phosphatase (AP) and periodic acid-Schiff
(PAS). In all cases, the analyses, as well as the selection of
positive and negative controls, were performed according to the
manufacturer’s  guidelines (Sigma, USA) [5]. To detect
surface antigen, aliquots of fresh UCB or cultured adherent
cells were immunolabelled with anti-human antibodies
CD51/61 (Pharmingen, USA), SH-2 (Ancell, USA) and
vimentin (Chemicon, USA), and the secondary antibodies:
FITC anti-mouse IgG diluted 1 : 100 (Zymed, USA).
Osteogenic potential of MSCs
Once sufficient numbers of cells were grown from UCB,
the cells were plated at 1,500 to 4,000 cells/cm
2 in growth
medium. Osteogenesis medium (growth medium with the
addition of 0.1 µmol/l dexamethasone [Sigma, USA], 0.05
mmol/l ascorbic acid-2-phosphate [Sigma, USA] and 10
mmol/l β-glycerophosphate [Sigma, USA]) was applied 24
h after plating [9,12]. The medium was changed every 3 to 4
days. Osteogenesis was assessed on day 14. The presence of
hydroxyapatite [(Ca10(PO4)6(OH)2)] nodules was visualized
with a 2% silver nitrate solution (Sigma, USA).
Neural differentiation of MSCs
The cells were plated at 1,000 to 2,000 cells/cm
2 in complete
medium with the addition of 10 ng/ml basic fibroblast growth
factor (bFGF; Roche, Switzerland), 10 ng/ml human epidermal
growth factor (hEGF; Roche, Switzerland) and 10 ng/ml
human neural growth factor (hNGF; Invitrogen, USA) for 14
days. To confirm the expression of neural related antigen, rabbit
polyclonal antibodies were used against neuron-specific
enolase (NSE; Chemicon, USA) and glial fibrillary acidic
protein (GFAP; Chemicon, USA). For the immunocytochemical
NSE and GFAP labeling, cells (cord blood passage 2) were
rinsed with PBS and then fixed with 3.7% formaldehyde in
PBS for 10 min at room temperature. They were then treated
with ice cold 100% methanol for 10 min, 100% acetone for
5 min, and then 0.4% Triton X-100 in PBS for 10 min with
triple PBS rinses between each treatment. The samples were
treated with 2% horse serum (Gibco-BRL, USA) and 2% goat
serum (Zymed, USA) in PBS containing 4% BSA (PBS/BSA)
for 100 min at 37
oC to block the non-specific binding of
primary antibodies. The antibodies were diluted in PBS/BSA
plus 2% horse sera or 2% goat sera at 1 : 200 for NSE and
1 : 200 for GFAP, respectively. The primary antibodies were
incubated with the cells for 1 h at 37
oC. The samples were
rinsed three times with PBS. The following fluorescent
secondary antibodies were added concurrently: FITC and
TRITC anti-rabbit antibodies (Zymed Laboratories, USA) that
were diluted 1 : 200 in PBS/BSA plus 2% horse sera and 2%
goat sera, respectively, for 45 min at 37
oC. The slides were
rinsed with PBS and then mounted in Gelvatol (Lab Vision,
USA). The fluorescence was visualized using a fluorescent
microscope.
Results
Establishment of primary culture
The whole cord blood mononuclear fraction was isolated
and then cultured. Attached cells were observed at 5-7 days
after the initial plating. The floating cells were removed
from the changed medium and then the attached cells were
subsequently passaged. Low-glucose medium and an acidic
environment facilitated the elimination of the hematopoietic
progenitor cells [9]. After 4 weeks of culture, the UCB-
derived MSCs were recognizable as adherent cells with a
fibroblast-like appearance (Fig. 1).In vitro neuronal and osteogenic differentiation of mesenchymal stem cells from human umbilical cord blood 345
Characteristics of adherent cells for MSCs culture
There are 2 types of adherent cells from the UCB:
osteoclast-like cells and mesenchymal-like cells. The
morphology of the osteoclast-like cells was heterogeneous
and elongated or oval/round shape with smooth borders, and
in certain cases the cells showed cytoplasmic extensions.
These cells were usually in contact with each other; however,
the most remarkable feature was the presence of multinucleated
cells with nuclei congregated around a central area. These
cells were positive for AP activity, but they were negative
for PAS (Fig. 3A). Osteoclast-related antigen CD51/61
(vitronectin receptor) was also expressed (Fig. 3C). The
initially adherent mesenchymal-like cells grew as spindle-
shaped cells, which developed into multi-polar fibroblastoid
cells. These cells then gradually reached confluency at about
30 days. Cytochemical analysis demonstrated that the
mesenchymal-like cells were positive for PAS (Fig. 2C),
but they were negative for AP activity. The cells showed
immunophenotypic marker positivity for mesenchym-
related antigens SH2 and vimentin (Fig. 2A).
Cord blood MSCs exhibit osteogenic potential
To induce osteogenic differentiation from the MSCs, we
used an osteogenic induction medium that consisted of β-
glycerol phosphate, ascorbic acid and dexamethasone. The
UCB MSCs formed hydroxyapatite, suggesting that MSCs
have osteogenic potential (identified by Von-Kossa staining)
(Fig. 4). However, unlike bone marrow MSCs, the UCB
MSCs did not show cuboidal morphology, which is a typical
aspect of osteoblast-enriched cultures derived from bone
marrow.
Cord blood MSCs express neural-specific antigens
To evaluate whether cord blood MSCs have an ability to
differentiate into neuronal cells, we cultured UCB MSCs in
neurogenic medium. When exposed to hEFG/hFGF/hNGF
for 2 weeks, the UCB MSCs expressed neural-specific
antigen and they showed some morphological features of
neural cells such as long multi-polar extensions and
Fig. 1. Initially adherent mesenchymal-like cells grew as spindle-
shaped or stellate-shaped cells that developed into multi-pola r
fibroblastoid cells. They gradually reached confluency at abou t
30 days. A; Primary culture day 14. B & C; Primary culture day
21. D; Primary culture day 30. B, C and D shows cell clusters. A
& D: ×100, B & C: ×200.
Fig. 2. Cytochemical analysis shows that the mesenchymal-like
cells were positive for PAS, but they were negative for AP activity.
The immunophenotyping of these cells showed positivity fo r
mesenchym-related antigen SH2. A; SH-2 (Endoglin) staining
with the mesemchymal-like cells. B; Phase contrast image, C;
PAS staining with mesenchymal-like cells. D; Negative contro l
(counterstained with hematoxylin). ×200.
Fig. 3. Osteoclast-like cells were positive for AP activity, bu t
they were negative for PAS. Osteoclast-related antigen CD51/61
(the vitronectin receptor) was also expressed. A; There was AP
staining with the osteoclast-like cells. B; Negative contro l
(counterstained with hematoxylin). C; Immunofluorescence assay
for CD51/61 with osteoclast like cells. D; Phase contrast.  ×200.346 Ki-Soo Park et al.
branching ends. After neuronal differentiation, the UCB
MSCs expressed NSE (Fig. 5A) and GFAP (Fig. 5D), which
are cytoskeletal proteins in neurons and astrocytes, respectively.
Therefore, the MSCs in human umbilical cord blood can
expand in vitro and differentiate into non-mesenchymal cells.
Discussion
The presence of mesenchymal stem/progenitor cells in
cord blood has recently been identified [5]. However, these
cells are known to poorly proliferate in vitro culture system.
Therefore, some researchers are skeptical about the presence
of human mesenchymal progenitor cells in umbilical cord
blood [20,26]. Despite the fact that bone marrow represents
the main available source of MSCs, the use of bone marrow-
derived cells is not always acceptable due to the high degree
of viral infection and the significant drop in cell number and
proliferative/differentiation capacity when the cells age.
UCB cells have many advantages because of the immaturity
of newborn cells compared with adult cells. In this study, we
showed that UCB-derived mononuclear cells, when cultured
in medium containing 10% FBS, were able to generate
adherent cells. In addition, we were able to induce successful
proliferation of mesenchymal-like cells (higher than 80%
confluency). However, we found that the nature of adherent
cells was not the same for all cases: the adherent cells
exhibited either an osteoclast-like or a mesenchymal-like
phenotype, and each was characterized by the following
features. First, approximately 40% of the cord blood collections
gave rise to cultures of adherent cells that displayed the
morphology and characteristics of multinucleated osteoclast-
like cells. These cells expressed markers for osteoclasts such
as a strong tartrate-resistant acid phosphatase activity and
the expression of CD51/CD61 [5,23,25]. Second, almost
60% of the cord blood cells gave rise to an adherent layer
that was initially formed by individual cells (70-80%) or
colonies of cells (20-30%), which rapidly gave rise to a well
established layer of fibroblastoid cells, and these cells showed
rapid growth. The adherent cells expressed mesenchymal
progenitor-related antigens SH2 and vimentin [5]. The
MSCs were also positive for PAS, and MSCs are known to
Fig. 4. Expression of the bone phenotype after exposure of UCB mesenchymal-like cells to differentiation stimuli. A, B & C; UCB
MSCs’ was morphologically changed (day 14), Phase contrast,  ×200. D, E & F; UCB MSCs’ osteogenesis as confirmed by calcium
accumulation, Von-Kossa staning, ×200.
Fig. 5. Pattern of the expression of neural specific antigens i n
UCB mssenchymal-like cells. A; Stained with NSE. B; Phase
contrast image. C; Stained with GFAP. D; Phase contrast. ( ×200).In vitro neuronal and osteogenic differentiation of mesenchymal stem cells from human umbilical cord blood 347
express antigens such as SH2, SH3, SH4, ASMA, MAB
1470, CD13, CD29, CD49e and CD54 [1,3,4,19]. Our
object for this study was to focus on whether mesenchymal
cell can be propagated in vitro and then purified into 2 types
of cells (mesenchymal cell & osteoclast cell). Therefore, in
order to purify MSCs, we tried to isolate the MSCs from
osteoclasts because there is the time difference to become
detached between the MSCs and osteoclasts during the
subculture, but these two types of cells could not be clearly
isolated. A further study is needed to clearly exclude the
osteoclasts from MSCs. Lee et al. [15] also tried negative
selection to sort the MSCs according to the negative lineage
markers (CD3, CD7, CD19, CD38 and glycophorin-A), yet
the resulting cell population was still heterogeneous. Therefore,
further investigations should be conducted on refining methods
to purify and expand MSCs from UCB. Nevertheless, we
obtained several findings from the present study. First of all,
we got a high ratio of MSCs among the attached cells from
much fresher UCB samples, and this suggest that this factor
is more important than the ratio gap of MSCs between the
preterm samples and full-term samples. Second, we also
tried to sort mesenchymal cells via a Magnetic Cell Separation
System (MACS; Miltenyi Biotec GmbH, Germany). Even
though the number of mesenchymal cells was much higher
than the number of osteoclast cells after MACS sorting, the
proliferation of mesenchymal cells was inhibited because
the osteoclast cells grew faster than the mesenchymal cells,
indicating that a high number of osteoclast cells can inhibit
the proliferation of mesenchymal cells (data not shown).
Therefore, in a further study, we need to find media that can
inhibit osteoclast cell proliferation with not affecting the
proliferation of mesenchymal cells after performing selection
with the right markers for mesenchymal cells. This is a key
to isolating MSCs from UCB and to maintain their good
condition for MSCs proliferation. However, in present
study, we used FBS for our research, and we need to find
methods to expand MSCs ex vivo without using FBS for
clinical use and performing cell therapy. Lee et al. [15] also
used the same culturing method as ours in their study. We
also demonstrated that MSCs are capable of differentiating
with bone and neural features in vitro. In the presence of
dexamethasone,  β-glycerol phosphate and ascorbate, the
MSCs expressed bone cell traits such as formation of
mineralizing colonies [3,12]. Moreover, MSCs exposed to a
defined neurogenic medium for 2 week were shown to have
some features of neural cells in culture, such as long multi-
polar extensions and branching ends that stained positive
with NSE for the neurons, and they stained positive for
GFAP in the astrocytes. The immunophenotype and functional
properties displayed by cord-blood-derived MSCs very closely
resembled the characteristics observed for bone marrow-
derived mesenchymal progenitor cells [3,6,19]. Yet in order
to get more evidence on the multipotency of mesenchymal
stem cells in human cord blood, the gene expression for
specific markers of neuronal or osteogenic cells should be
investigated. It has been shown that mature osteoclast or
their progenitors are circulating in umbilical cord blood
[5,21]. The presence of mesenchymal progenitor cells in
cord blood is rational because it can be hypothesized that
both hematopoietic and mesenchymal progenitors are
traveling, via cord blood, from early fetal haematopoietic
sites to the newly formed bone marrow [18,24]. In this
study, despite the relatively low number of harvested UCB
cells that could be developed into MSCs, like was also
shown by other researchers, our results suggest that cord
blood might be rich in mesenchymal progenitors, the same
as the case for haematopoietic progenitors [22,27]. It was
thought that the time from sampling to primary culture, the
proper technique and the maintenance temperature may be
important factors to collect MSCs. Based on their large ex
vivo expansion capacity, as well as on their differentiation
potential, cord blood-derived mesenchymal cells may be an
attractive cell source for cellular or gene transfer therapy for
treating such incurable disease as neuro-degenerative disease.
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